Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01828034
Title First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center, Novartis
Indications

biliary tract cancer

Therapies

Binimetinib + Cisplatin + Gemcitabine

Age Groups: adult
Covered Countries USA


No variant requirements are available.